Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Earlier versions of a spending cuts package passed through Congress targeted PEPFAR. But the White House, concerned about ...

In a letter, the Long Beach Democrat asked Health and Human Services Secretary Robert F. Kennedy Jr. to produce documents ...

Adults who switched from daily ART to long-acting cabotegravir-rilpivirine showed high levels of virologic suppression, high ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

HIV care and its related outcomes in South Carolina were defined by racial disparities, specifically in retention in care, ...